TrialAnnals of oncology : official journal of the European Society for Medical Oncology2018

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.

M Gross-Goupil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.